bullish
Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48
395 Views23 Oct 2020 10:37
This article analyzed two core products from RemeGen: RC18 and RC 48. The commercialization of these two products would have direct impact on the performance of RemeGen after listing.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- China Healthcare Weekly (Oct.30)02 Nov 2020
- Jiangsu Hengrui Medicine (600276 CH) - Q3 Performance Improved with Promising Innovative Pipeline28 Oct 2020
- JW Therapeutics - Concerns Are in the Short Term but Still Promising in the Long Term28 Oct 2020
- Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC4823 Oct 2020
- Pre-IPO JD Health (JDH.HK) - A Better Candidate of Online Healthcare Business In China?15 Oct 2020
- A Different Angle - Simcere Pharmaceutical VS Everest Medicines (01952.HK)11 Oct 2020
- RemeGen (荣昌生物) Pre-IPO: Thoughts on Valuation of RC18 and RC4813 Aug 2020
x